Michael Saidel, MD
Cornea and External Diseases Specialist · Sonoma, CANPI 1184780330
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), consulting fees and other — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 36.5% of the total. Reporting peaked in 2019 at $26,378 and has fallen 96.2% since, to $1,007 in 2025.
Across 244 payments — averaging $210.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$19K
- Glaukos Corporation$8K
- Eyepoint US, Inc.$8K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$7K
- Integra Lifesciences Corporation$4K
- Kala Pharmaceuticals, Inc.$1K
- plus $4K from 22 others
Across 75 payments — averaging $925.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$69K
What the payments were for
- Consulting fees$9,00018%
- Speaking & faculty fees$24,20047%
- Travel & lodging$4,2758%
- Food & beverage$6,28712%
- Education$980%
- Gifts$750%
- Other$7,47515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 37 | $18,777 |
| Glaukos Corporation | 16 | $8,208 |
| Eyepoint US, Inc. | 17 | $8,091 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $7,089 |
| Integra Lifesciences Corporation | 2 | $3,900 |
| Kala Pharmaceuticals, Inc. | 7 | $1,380 |
| Alcon | 37 | $1,042 |
| AbbVie(2 entities) | 27 | $478 |
| Bausch & Lomb Americas Inc. | 17 | $302 |
| Dompe US, Inc. | 9 | $289 |
| Harrow Eye, LLC | 6 | $272 |
| Oyster Point Pharma, Inc. | 10 | $267 |
| Biotissue Holdings Inc. | 7 | $246 |
| Aerie Pharmaceuticals, Inc. | 3 | $201 |
| Novartis | 8 | $136 |
| Tarsus Pharmaceuticals, Inc. | 5 | $112 |
| Mallinckrodt Hospital Products Inc. | 1 | $98 |
| Sight Sciences, Inc. | 4 | $84 |
| Astellas Pharma US Inc | 3 | $77 |
| Carl Zeiss Meditec, Inc. | 2 | $75 |
| Thea Pharma Inc. | 3 | $73 |
| Carl Zeiss Meditec AG | 3 | $58 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $46 |
| Rayner Intraocular Lenses Limited | 2 | $43 |
| Beaver-visitec International, Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Amgen | 1 | $15 |
| NEW World Medical,inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$18,192
- DEXYCU$7,803
- PROLENSA$4,633
- BIOFIX$3,900
- BIODOPTIX$3,900
- BIODFACTOR$3,900
- BIODRESTORE$3,900
- LOTEMAX SM$2,225
- EYSUVIS$1,300
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$157
- Photrexa Viscous and Photrexa$150
- ReSTOR$142
How this compares
$51,411 in reported general payments places this provider in the 85th percentile of 50 cornea and external diseases specialist providers in California.
See all cornea and external diseases specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 70 | $54,924 |
| XiidraLifitegrast | 42 | $49,962 |
| CequaCyclosporine | 25 | $26,603 |
| LumiganBimatoprost | 20 | $12,921 |
| Cyclosporine | 25 | $10,431 |
| Travoprost | 31 | $7,880 |
| Loteprednol Etabonate | 50 | $7,163 |
| Latanoprost | 308 | $5,984 |
| RhopressaNetarsudil Mesylate | 13 | $5,610 |
| Prednisolone Acetate | 106 | $4,956 |
| Fluorometholone | 37 | $2,823 |
| Timolol Maleate | 90 | $2,277 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 43 | $2,005 |
| MoxifloxacinMoxifloxacin Hcl | 67 | $1,494 |
| Brimonidine Tartrate | 18 | $1,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $478 | $67,84590 claims |
| Bausch & Lomb Americas Inc.Xiidra | $302 | $49,96242 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $18,777 | $26,60325 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $7,089 | $7,16350 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $201 | $5,61013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 cornea and external diseases specialist providers in California.
Other cornea and external diseases specialist in Sonoma
- Sumit GargIrvine$808K
- Jillian ChongBeverly Hills$113K
- Tyson KimSan Francisco$91K
- Edward MancheStanford$78K
- Michael SavetskyCulver City$63K
- Matthew WadeIrvine$38K
- Lawrence ChaoIrvine$36K
- William ChristianSanta Monica$33K
- Alexander FosterEncinitas$29K
- Jimmy LeeIrvine$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.